Eli Lilly and Company $LLY Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. trimmed its Eli Lilly stake by 0.2%, selling 761 shares, but still held 401,209 shares valued at about $465.9 million, its seventh-largest portfolio position.
• Eli Lilly reported quarterly EPS of $7.48, beating the $5.71 consensus, while revenue rose 38.6% year over year to $24.4 billion.
• Analyst sentiment was broadly positive: the stock had a “Moderate Buy” consensus rating and a $1,404.14 average price target, with several firms recently raising their targets.

Candriam S.C.A. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 401,209 shares of the company's stock after selling 761 shares during the quarter. Eli Lilly and Company accounts for 2.1% of Candriam S.C.A.'s portfolio, making the stock its 7th biggest holding. Candriam S.C.A.'s holdings in Eli Lilly and Company were worth $465,927,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. American State Bank Iowa boosted its holdings in shares of Eli Lilly and Company by 9.8% in the third quarter. American State Bank Iowa now owns 348 shares of the company's stock valued at $403,000 after purchasing an additional 31 shares during the period. Chapman Investment Management LLC raised its position in Eli Lilly and Company by 197.5% during the 3rd quarter. Chapman Investment Management LLC now owns 3,317 shares of the company's stock valued at $3,838,000 after purchasing an additional 6,720 shares in the last quarter. Cooper Haims Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 27.9% in the 3rd quarter. Cooper Haims Advisors LLC now owns 399 shares of the company's stock worth $462,000 after buying an additional 87 shares during the period. Henderson Brothers Financial Partners LLC lifted its holdings in shares of Eli Lilly and Company by 5.8% in the 3rd quarter. Henderson Brothers Financial Partners LLC now owns 382 shares of the company's stock worth $442,000 after buying an additional 21 shares during the period. Finally, Uhlmann Price Securities LLC lifted its holdings in shares of Eli Lilly and Company by 0.4% in the 3rd quarter. Uhlmann Price Securities LLC now owns 4,525 shares of the company's stock worth $5,236,000 after buying an additional 17 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 1.3%

Eli Lilly and Company stock opened at $1,372.15 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The firm has a market cap of $1.29 trillion, a P/E ratio of 44.54, a P/E/G ratio of 1.62 and a beta of 0.40. The business has a fifty day moving average of $1,215.24 and a two-hundred day moving average of $1,101.16. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same period last year, the business posted $7.02 EPS. The business's revenue was up 38.6% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LLY. UBS Group raised their price target on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, October 31st. Scotiabank upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a "sector outperform" rating in a research note on Friday, October 30th. Argus increased their target price on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Finally, Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $1,404.14.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.